Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: - | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Endpoint summary
Administrative data
Description of key information
Oral:
The acute oral study is performed according to OECD Guideline 425 under GLP. The oral LD50 of the test item when administered to female rats is estimated to be 310.2 mg/kg.
Dermal:
The acute dermal study is performed according to OECD Guideline 402 under GLP. The dermal LD50 of the test item was greater than 2000 mg/kg in male and female rats.
Key value for chemical safety assessment
Acute toxicity: via oral route
Link to relevant study records
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- From July 14, 2008 to August 29, 2008
- Reliability:
- 1 (reliable without restriction)
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 425 (Acute Oral Toxicity: Up-and-Down Procedure)
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Test type:
- up-and-down procedure
- Limit test:
- no
- Specific details on test material used for the study:
- Test material name in the study: PF-03394197-11
- Species:
- rat
- Strain:
- Crj: CD(SD)
- Sex:
- female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Rationale for alternative/additional species to rat (if applicable)
- Source: Charles River Laboratories, Portage, Michigan
- Females (if applicable) nulliparous and non-pregnant: [yes/no]
- Rationale for use of males (if applicable)
- Age at study initiation: Approximately 7 weeks
- Weight at study initiation: Female: 184 to 273 g
- Fasting period before study: overnight
- Housing: Individually in stainless steel suspended wire mesh caging
- Historical data:
- Diet (e.g. ad libitum): Block Lab Diet® Certified Rodent Diet #5002, PMI Nutrition International, Inc. Ad libitum, except during designated periods.
- Water (e.g. ad libitum): Automatic watering system, Ad libitum, except during designated periods.
- Acclimation period: 7 to 32 Days
- Microbiological status when known
- Method of randomisation in assigning animals to test and control groups
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 17.8 to 26.1°C
- Humidity (%): 30 to 70%
- Air changes (per hr):
- Photoperiod (hrs dark / hrs light): Fluorescent lighting was provided for approximately 12 hours per day. - Route of administration:
- oral: gavage
- Vehicle:
- methylcellulose
- Details on oral exposure:
- MAXIMUM DOSE VOLUME APPLIED: 10 mL/kg
DOSAGE PREPARATION (if unusual):
The test article, was used as received from the Sponsor, and a correction
factor of 1.344 was applied to correct for the ratio of molecular weight of the salt to the base
of the test article. Dose preparation was performed by mixing the appropriate amount of test
article, with the appropriate amount of vehicle, to achieve the required nominal concentrations for the limit test, 200 mg/mL, and main tests, 17.5 and 55 mg/mL.
CLASS METHOD (if applicable)
- Rationale for the selection of the starting dose: limit dose level of 2000 mg/kg - Doses:
- 2000, 175, 550, 175, 550, 175, and 550 mg/kg
- No. of animals per sex per dose:
- 1 or 3 females
- Control animals:
- no
- Details on study design:
- - Duration of observation period following administration: 14 days
- Frequency of observations and weighing: Observations for morbidity, mortality, injury, and the availability of food and water were conducted twice daily for all animals. Observations for clinical signs were conducted on each surviving animal at 0.5, 2, and 4 hours postdose on the day of dosing, and were continued once daily for no longer than 13 additional days, dependant on survival. Body weights were measured and recorded prior to test article administration on Day 1, and weekly thereafter. Additional body weights were taken for two animals found dead prior to submission to necropsy at dose levels of 2000 mg/kg and 550 mg/kg.
- Necropsy of survivors performed: Necropsy examinations were performed under procedures approved by a veterinary pathologist on all animals found dead, and all surviving animals at the scheduled necropsy. The surviving animals were euthanized by carbon dioxide inhalation, and euthanasia was confirmed by exsanguination via the abdominal vena cava. The animals were examined carefully for external abnormalities including masses. The skin was reflected from a ventral midline incision, and any abnormalities were identified and correlated with antemortem
findings. The abdominal, thoracic, and cranial cavities were examined for abnormalities, and the organs removed, examined, and the tissues and carcasses were discarded. - Key result
- Sex:
- female
- Dose descriptor:
- LD50
- Effect level:
- 310.2 mg/kg bw
- Based on:
- test mat.
- Mortality:
- All animals died on Day 2 at 2000 and 550 mg/kg dose level.
- Clinical signs:
- Impaired limb function, decreased activity, ataxia, slow and difficult breathing, salivation, lacrimation, and partially closed eyelids were observed following the limit dose of 2000 mg/kg, and prior to the animal being found dead. Impaired limb function, decreased activity, ataxia, slow and difficult breathing, prostration, hunched posture, salivation, skin cold to touch, red material around nose, lacrimation, and partially closed eyelids, and decreased feces were all observed in at least one of the three animals dosed at 550 mg/kg. Clinical findings observed following the administration at 550 and 2000 mg/kg were considered to be related to test article administration.
- Body weight:
- No effect of test article administration was observed on the body weights or body weight gains of the three animals at 175 mg/kg that survived to the scheduled necropsy on Day 15.
- Gross pathology:
- No test article-related macroscopic observations were made in study animals. Macroscopic observations were usual and/or incidental in rats of this type and age.
- Interpretation of results:
- Category 4 based on GHS criteria
- Conclusions:
- The oral LD50 of the test item when administered to female rats is estimated to be 310.2 mg/kg.
- Executive summary:
The acute oral study is performed according to OECD Guideline 425 under GLP. The oral LD50 of the test item when administered to female rats is estimated to be 310.2 mg/kg.
Reference
Endpoint conclusion
- Endpoint conclusion:
- adverse effect observed
- Dose descriptor:
- LD50
- Value:
- 310.2 mg/kg bw
- Quality of whole database:
- reliable without restrictions
Acute toxicity: via inhalation route
Endpoint conclusion
- Endpoint conclusion:
- no study available
Acute toxicity: via dermal route
Link to relevant study records
- Endpoint:
- acute toxicity: dermal
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- From July 18, 2008 to August 20, 2008
- Reliability:
- 1 (reliable without restriction)
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 402 (Acute Dermal Toxicity)
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Test type:
- fixed dose procedure
- Limit test:
- yes
- Specific details on test material used for the study:
- Test material name in the study: PF-03394197-11
Lot Number: PF-01/115802/138A - Species:
- rat
- Strain:
- Crj: CD(SD)
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Rationale for alternative/additional species to rat (if applicable)
- Source: Charles River, Portage, Michigan
- Females (if applicable) nulliparous and non-pregnant: [yes/no]
- Rationale for use of males (if applicable)
- Age at study initiation: Approximately 7 weeks
- Weight at study initiation: Male: 220 to 225 g Female: 167 to 176 g
- Fasting period before study:
- Housing: Individual, stainless steel suspended wire mesh-type cages
- Historical data:
- Diet (e.g. ad libitum): Block Lab Diet® Certified Rodent Diet #5002, PMI Nutrition International, Inc. Ad libitum.
- Water (e.g. ad libitum): Automatic watering system, Ad libitum.
- Acclimation period: 7 days
- Microbiological status when known
- Method of randomisation in assigning animals to test and control groups
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 22 (±3) °C
- Humidity (%): 30 to 70%
- Air changes (per hr):
- Photoperiod (hrs dark / hrs light): Fluorescent lighting was provided for approximately 12 hours per day. The dark cycle was interrupted intermittently due to study-related activities. - Type of coverage:
- occlusive
- Vehicle:
- other: Mineral oil
- Details on dermal exposure:
- TEST SITE
- Area of exposure: back of each animal
- % coverage: no less than 10% of the body surface area
- Type of wrap if used: the area was wrapped with gauze and secured with a non-irritating tape.
REMOVAL OF TEST SUBSTANCE
- Washing (if done): the wrappings were removed and the residual test article was removed using tepid tap water.
- Time after start of exposure: 24 hours - Duration of exposure:
- 24 hours
- Doses:
- 2000 mg/kg
- No. of animals per sex per dose:
- 5 males and 5 females
- Control animals:
- no
- Details on study design:
- - Duration of observation period following administration: 14 days
- Frequency of observations and weighing: The test animals were observed for clinical signs approximately 0.5, 2, and 4 hours after dosing on Day 1. Thereafter, the animals were observed for clinical signs once daily for 14 days. Observations included, but were not limited to, evaluation of the skin, fur, eyes, ears, nose, oral cavity, thorax, abdomen, external genitalia, limbs and feet, respiratory and circulatory effects, autonomic effects such as salivation, nervous system effects including tremors, convulsions, reactivity to handling, and bizarre behavior. Individual body weights were obtained on the day of arrival, just prior to test article administration (Day 1) and
weekly thereafter.
- Necropsy of survivors performed: Complete necropsy examinations were performed under procedures approved by a veterinary pathologist on all animals euthanized at scheduled necropsies. Euthanasia was by carbon dioxide inhalation followed by exsanguination from the abdominal vena cava. The animals were examined carefully for external abnormalities including palpable masses. The skin was reflected from a ventral midline incision, and any subcutaneous masses were identified and correlated with antemortem findings. The abdominal, thoracic, and cranial cavities were examined for abnormalities, and the organs were removed, examined, and the tissues and carcasses were discarded. - Key result
- Sex:
- male/female
- Dose descriptor:
- LD50
- Effect level:
- > 2 000 mg/kg bw
- Based on:
- test mat.
- Mortality:
- All animals survived to the scheduled necropsy on Day 15.
- Clinical signs:
- There were no treatment-related clinical findings. There were clinical findings that may have
been due to the wrapping and the use of Elizabethan collars that included red or brown
material around the eyes and nose and brown skin discoloration of the thoracic region and
sparseness of hair in the abdominal region which were observed very occasionally. - Body weight:
- There were no treatment-related changes in body weight gains. The body weight gain of one
female animal (number 3006) was slightly lower than expected; however the body weight
gains of the remaining animals over the two week study period were considered normal. - Gross pathology:
- No test article-related macroscopic observations were made in male or female rats.
- Interpretation of results:
- GHS criteria not met
- Conclusions:
- The dermal LD50 of the test item was greater than 2000 mg/kg in male and female rats.
- Executive summary:
The acute dermal study is performed according to OECD Guideline 402 under GLP. The dermal LD50 of the test item was greater than 2000 mg/kg in male and female rats.
Reference
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- LD50
- Value:
- > 2 000 mg/kg bw
- Quality of whole database:
- reliable without restrictions
Additional information
Justification for classification or non-classification
Acute toxicity:
Oral, OECD 425: LD50 is 310.2 mg/kg body weight;
Dermal, OECD 402: LD50 > 2000 mg/kg body weight.
Therefore in accordance with Regulation (EC) No. 1272/2008 (amended by 286/2011) Table 3.1.1 , this substance should be classified for Acute oral Cat 4 and not classified for Acute dermal toxicity.
Specific target organ toxicity-single exposure:
No abnormalities were noted at necropsy in both acute oral and dermal studies.
As there were no effects considered to support classification for Category 1 and 2 observed. Therefore in accordance with Regulation (EC) No. 1272/2008 Table 3.8.1 and 3.8.2, this substance should not be classified.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
